Primary mucinous adenocarcinoma of the urethra: A clinicopathological analysis of 35 cases

Abstract

AimPrimary mucinous adenocarcinoma of the urethra represents an extremely rare entity. We sought to characterise further these tumours’ clinicopathological, immunohistochemical and molecular features.Methods and resultsThirty‐five cases were identified, occurring in 18 males and 17 females. The mean age at diagnosis was 65 years (28–89 years). The main presentation symptoms were haematuria and urinary outlet obstruction. Microscopic analysis revealed that all 35 tumours have stromal dissection by mucin. Ten tumours showed villoglandular dysplasia, nine showed mucinous metaplasia, two showed adenocarcinoma in situ and four showed signet ring cell features. All tumours were immunopositive for CEA, while immunonegative for nuclear β‐catenin; 19 of 23 (83%) expressed high molecular weight cytokeratin; 19 of 33 (58%) CK7; 28 of 34 (82%) CK20; 32 of 35 (91%) CDX2; 22 of 27 (81%) cadherin‐17 (CDH‐17); 26 of 29 (90%) SATB2; and one of 31 (3%) GATA3. Mismatch repair gene products, including MLH1, PMS2, MSH2 and MSH6, were immunopositive, suggesting the MSI‐low genotype of mucinous adenocarcinoma of the urethra. BRAF V600E and ALK rearrangements were not detected. During the mean follow‐up of 20 months, nine patients either developed distant metastasis or succumbed to the illness.ConclusionOur study, encompassing the most extensive series of 35 cases of primary mucinous adenocarcinoma of the urethra, provides crucial insights into its precise diagnosis, management and potential targeted treatments. We found a greater CDX2, SATB2 and CDH17 sensitivity in these urethral tumours for the first time, to our knowledge. We identified characteristics such as an MSI‐low profile, non‐V600E BRAF mutations and an absence of ALK rearrangements.